Benralizumab Overview

Introduction of Benralizumab

Benralizumab is a humanized monoclonal antibody which binds to the α subunit of the Interleukin-5 receptor (IL-5R), and indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. As Interleukin-5(IL-5) is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the treatment of asthma. With the trade name Fasenra, benralizumab has been approved for marketing by FDA on November 14, 2017.

Mechanism of Action of Benralizumab

As eosinophils are the dominating effector cells in asthma, inhibition of eosinophilia, theoretically would result in a decreased airway injury, mucus hypersecretion and bronchial hyper-responsiveness. IL-5 induces an inflammatory response by interacting with eosinophils through targeting the Interleukin-5 receptor (IL-5R) expressed in eosinophils, basophils and some mast cells. IL-5R is a heterodimer, composed of a monomeric α and a dimeric β chain. The α chain specifically binds with IL-5 with low affinity, however, the ligand binding of IL-5 and IL-5Rα is followed by hetero-oligomerization of α and β subunits that leads to further proximity of β subunit intracellular domains producing a high-affinity phenotype. Benralizumab, binds with high affinity to of IL-5Rα, which in turn blocks the ligand binding of IL-5 as well as other putative ligands (such as IL-3, IL-4, IL-13 and GM-CSF), thereby no hetero-oligomerization of α and β subunits takes place and thus no signal transduction occurs (Figure 1).

Figure 1 Mechanism of Action of Benralizumab

Clinical Projects of Benralizumab *

Approved Drugs of Benralizumab **

INN (trade name)	Therapeutic area	Dose	Strength	Route	Company	Marketing start	Market
Fasenra®	Asthma	Injection, solution	30 mg/mL	Subcutaneous	AstraZeneca Pty Ltd	April 2, 2018
Fasenra®	Asthma	Injection, solution	30 mg/mL	Subcutaneous	AstraZeneca AB	November 14, 2017
Fasenra®	Asthma	Injection, solution	30 mg/mL	Subcutaneous	Astra Zeneca	April, 2018
Fasenra®	Asthma	Injection, solution	30 mg/mL	Subcutaneous	Astra Zeneca	November 14, 2017

What We Provide

Therapeutic Antibody

Benralizumab

We provide high-quality Benralizumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Benralizumab&cntry=&state=&city=&dist=

** Information presented in the table were collected from the following websites:
https://search.tga.gov.au/s/search.html?collection=tga-websites-web&query=Benralizumab&op=Search
http://www.ema.europa.eu/ema/index.jsp?curl=search.jsp&q=Benralizumab+&btnG=Search&mid=
https://www.kegg.jp/medicus-bin/search_drug?search_keyword=Benralizumab
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process

For research use only. Not intended for any clinical use.